DDInter94 DDInter704
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Zinc sulfate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Everolimus (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Everolimus (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)